share_log

Chairman of Zhongzhi Pharmaceutical Holdings Zhi Tian Lai Buys More Stock

Chairman of Zhongzhi Pharmaceutical Holdings Zhi Tian Lai Buys More Stock

中智藥業控股董事長智天來購買更多股票
Simply Wall St ·  04/05 06:38

Zhongzhi Pharmaceutical Holdings Limited (HKG:3737) shareholders (or potential shareholders) will be happy to see that the Chairman, Zhi Tian Lai, recently bought a whopping HK$4.0m worth of stock, at a price of HK$1.18. While that only increased their holding size by 0.7%, it is still a big swing by our standards.

中智藥業控股有限公司(HKG: 3737)的股東(或潛在股東)將很高興看到主席賴智天最近以1.18港元的價格購買了價值高達400萬港元的股票。儘管這僅使他們的持股規模增加了0.7%,但按照我們的標準,這仍然是一個很大的波動。

Zhongzhi Pharmaceutical Holdings Insider Transactions Over The Last Year

中智藥業控股去年內幕交易

Notably, that recent purchase by Zhi Tian Lai is the biggest insider purchase of Zhongzhi Pharmaceutical Holdings shares that we've seen in the last year. So it's clear an insider wanted to buy, even at a higher price than the current share price (being HK$1.16). Their view may have changed since then, but at least it shows they felt optimistic at the time. To us, it's very important to consider the price insiders pay for shares. As a general rule, we feel more positive about a stock when an insider has bought shares at above current prices, because that suggests they viewed the stock as good value, even at a higher price. The only individual insider to buy over the last year was Zhi Tian Lai.

值得注意的是,智天來最近的一次收購是我們去年對中智藥業控股股票的最大一次內幕收購。因此,很明顯,即使價格高於當前股價(1.16港元),內部人士也想買入。從那以後,他們的觀點可能發生了變化,但至少這表明他們當時感到樂觀。對我們來說,考慮內部人士爲股票支付的價格非常重要。通常,當內部人士以高於當前的價格購買股票時,我們對股票的看法會更加樂觀,因爲這表明他們認爲股票即使價格更高,也物有所值。去年唯一買入的內部人士是智天來。

Zhi Tian Lai bought 7.16m shares over the last 12 months at an average price of HK$1.27. The chart below shows insider transactions (by companies and individuals) over the last year. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!

智天來在過去的12個月中以1.27港元的平均價格購買了716萬股股票。下圖顯示了去年的內幕交易(公司和個人)。如果你點擊圖表,你可以看到所有的個人交易,包括股價、個人和日期!

insider-trading-volume
SEHK:3737 Insider Trading Volume April 4th 2024
SEHK: 3737 內幕交易量 2024 年 4 月 4 日

Zhongzhi Pharmaceutical Holdings is not the only stock that insiders are buying. For those who like to find winning investments this free list of growing companies with recent insider purchasing, could be just the ticket.

中智藥業控股並不是內部人士唯一買入的股票。對於那些喜歡尋找獲利投資的人來說,這份最近有內幕收購的成長型公司的免費清單可能就是入場券。

Insider Ownership Of Zhongzhi Pharmaceutical Holdings

中智藥業控股的內部所有權

I like to look at how many shares insiders own in a company, to help inform my view of how aligned they are with insiders. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. Zhongzhi Pharmaceutical Holdings insiders own about HK$639m worth of shares (which is 64% of the company). Most shareholders would be happy to see this sort of insider ownership, since it suggests that management incentives are well aligned with other shareholders.

我喜歡看看內部人士在一家公司擁有多少股票,以幫助我了解他們與內部人士的看法。通常,內部人士的所有權越高,內部人士長期建立公司的可能性就越大。中智藥業控股內部人士擁有價值約6.39億港元的股份(佔該公司64%的股份)。大多數股東會很高興看到這種內部所有權,因爲這表明管理層的激勵措施與其他股東非常一致。

What Might The Insider Transactions At Zhongzhi Pharmaceutical Holdings Tell Us?

中智藥業控股的內幕交易可能告訴我們什麼?

It is good to see the recent insider purchase. We also take confidence from the longer term picture of insider transactions. When combined with notable insider ownership, these factors suggest Zhongzhi Pharmaceutical Holdings insiders are well aligned, and quite possibly think the share price is too low. That's what I like to see! So while it's helpful to know what insiders are doing in terms of buying or selling, it's also helpful to know the risks that a particular company is facing. Every company has risks, and we've spotted 1 warning sign for Zhongzhi Pharmaceutical Holdings you should know about.

很高興看到最近的內幕收購。我們還從內幕交易的長期前景中汲取信心。再加上顯著的內部所有權,這些因素表明中智藥業控股內部人士意見一致,很可能認爲股價過低。這就是我喜歡看到的!因此,雖然了解內部人士在買入或賣出方面的所作所爲很有幫助,但了解特定公司面臨的風險也很有幫助。每家公司都有風險,我們發現了一個你應該知道的中智藥業控股的警告信號。

Of course Zhongzhi Pharmaceutical Holdings may not be the best stock to buy. So you may wish to see this free collection of high quality companies.

當然,中智藥業控股可能不是最好的買入股票。因此,您可能希望看到這個免費的高質量公司集合。

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

就本文而言,內部人士是指向相關監管機構報告其交易的個人。我們目前只考慮公開市場交易和私下處置的直接利益,不包括衍生品交易或間接權益。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論